DRUG INTERNATIONAL LIMITED

What DRUG INTERNATIONAL LIMITED does

Drug International Limited is a Bangladesh-based pharmaceutical manufacturer incorporated in 1974 as a Private Limited Company, operating through three product divisions: allopathic pharmaceuticals (Drug), traditional herbal products, and Unani medicine. The company manufactures a broad therapeutic portfolio including oncology generics (e.g., Etoposide, Doxorubicin, Paclitaxel, Sorafenib), cardiovascular drugs (Rivaroxaban), steroids (Methylprednisolone, Deflazacort), and vitamins (Folinic acid), distributed to hospitals, pharmacies, and healthcare institutions in Bangladesh and exported to over 30 countries across South Asia, Africa, the Middle East, and Southeast Asia.

Its core technology platform is built around four manufacturing facilities in Tongi/Gazipur, including a state-of-the-art oral solid dosage plant established in 1985, a dedicated oncology production department for cytotoxic handling, soft gelatin capsule manufacturing capability (pioneered in Bangladesh in 1990), and a separate herbal/Unani production facility. Manufacturing is conducted under WHO cGMP compliance, supported by an in-house QC laboratory, Product Development Laboratory, modern water treatment, and an Effluent Water Treatment Plant.

The revenue model is B2B pharmaceutical product sales on a quote-based, multi-year contract basis, with pricing not publicly disclosed. Go-to-market is direct sales to domestic healthcare providers combined with direct export sales to international buyers. The company holds WHO cGMP, BAB (Bangladesh Accreditation Board), and Afghanistan Ministry of Public Health certifications, and reports no parent company, no institutional investors, and no disclosed management team.

Name

DRUG INTERNATIONAL LIMITED

Legal name

Drug International Limited

Website

https://drug-international.com

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

251–500 employees

Short description

Drug International Limited is a Bangladesh-based pharmaceutical manufacturer founded in 1974, producing generics, oncology, cardiovascular, steroid, herbal, and Unani medicines across four facilities and exporting to over 30 countries via B2B sales.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Oncology medications
• Soft gelatin capsules
• Herbal medicine products
• Unani formulations

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical products including generics, specialty drugs in oncology, cardiovascular, steroids, vitamins, and other therapeutic categories. Products are sold domestically in Bangladesh and exported to international markets across South Asia, Africa, Middle East, and Southeast Asia.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Drug International Limited manufactures and markets a broad portfolio of finished pharmaceutical products, including generic drugs across oncology, cardiovascular, anti-diabetic, steroid, vitamin, antibiotic, anticoagulant, and NSAID therapeutic categories, along with herbal medicinal products and traditional Unani formulations. Production occurs at WHO cGMP-certified facilities in Bangladesh, and finished products are supplied to healthcare providers both domestically and across more than 30 international markets in the USA, Canada, Europe, Africa, and Asia.

Product overview

Drug International Limited is a leading pharmaceutical company in Bangladesh operating across three divisions: DRUG (pharmaceuticals), HERBAL, and UNANI. The pharmaceutical portfolio includes oncology medications (Toposar, Dobixin, Mylostat, Sonib, Ontaxel-30, Epiruba-50, Mes-D), cardiovascular treatments (Varox), steroids (Depomed, Dezco), and vitamins (Foly). The company pioneered soft gelatin capsule formulation in Bangladesh and operates WHO-cGMP certified manufacturing facilities. The Herbal and Unani divisions offer natural wellness products rooted in traditional medicine.

Differentiator

Problem solved

Functional benefit

Brands

• Herbal Division: Herbal products division offering natural remedies combining traditional knowledge with modern technology for balanced health.
• Unani Division

Products and services

• Pharmaceutical Products (Allopathic) A broad portfolio of finished generic pharmaceutical medicines across multiple therapeutic categories (oncology, cardiovascular, anti-diabetic, steroids, vitamins, antibiotics, anticoagulants, and NSAIDs) manufactured at WHO cGMP-certified facilities and supplied on a B2B basis to healthcare providers, hospitals, and pharmacies in Bangladesh and more than 30 international markets.
• Herbal Products Finished herbal medicinal products manufactured and marketed as a dedicated product division, supplying plant-based remedies to healthcare providers and pharmacies through the company's B2B distribution channels.
• Unani Products Traditional Unani medicinal products produced and marketed as a dedicated product division, supplied through B2B channels to healthcare providers alongside the company's allopathic and herbal product lines.
• Soft Gelatin Capsules Finished soft gelatin capsule dosage forms manufactured at WHO cGMP-certified facilities, representing a pioneering capability in the Bangladesh pharmaceutical market and supplied across the company's therapeutic categories to healthcare providers.

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Healthcare Pharmaceuticals: Bangladeshi specialty pharmaceutical manufacturer with focus on oncology, cardiovascular, and chronic disease therapies. Closely comparable therapeutic emphasis and export footprint.
• ACI Limited (Pharma Division): Diversified Bangladeshi conglomerate with a sizable pharmaceutical manufacturing arm serving domestic and export markets. Comparable B2B pharma distribution and manufacturing capabilities.
• Square Pharmaceuticals: Largest pharmaceutical company in Bangladesh, manufacturing generics across similar therapeutic categories with significant export presence. Closest direct comparable for domestic-market share, manufacturing footprint, and product mix.
• Eskayef Pharmaceuticals: Bangladeshi generics manufacturer with WHO cGMP facilities and a strong oncology and specialty product line. Highly comparable therapeutic mix and regulatory positioning.
• Incepta Pharmaceuticals: One of the top Bangladeshi pharma manufacturers, producing generics, oncology, and biotech products domestically and exporting internationally. Directly comparable across product portfolio and therapeutic coverage.
• Beximco Pharmaceuticals: Major Bangladeshi generic manufacturer with strong export business to developed and emerging markets, including the first Bangladesh-approved generic for the US market. Comparable in scale, product breadth, and export orientation.
• Renata Limited: Leading Bangladeshi pharmaceutical and animal health company with diversified generic portfolio and significant exports. Comparable scale, regulatory standing, and therapeutic breadth.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest generic pharmaceutical manufacturer with global operations, including emerging-market generics and specialty pharma. Comparable generic manufacturing platform and emerging-market export reach.
• Aurobindo Pharma: Large Indian generic manufacturer with extensive emerging-market exports, particularly in Africa and Asia — geographies overlapping with Drug International's footprint. Comparable generic FDF manufacturing and export-oriented model.
• Cipla: Indian global generic and specialty pharma major with deep emerging-market presence in respiratory, oncology, and cardiovascular — categories where Drug International also operates. Comparable product mix and emerging-market export thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@druginternationalltd.6126
• Facebookfacebook.com/drugintltd
• LinkedInlinkedin.com/company/druginternationallimited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DRUG INTERNATIONAL LIMITED